Reduction of Nephrotoxicity Associated with Amphotericin B Deoxycholate

Johnson, James R.
January 2004
Clinical Infectious Diseases;1/15/2004, Vol. 38 Issue 2, p303
Academic Journal
Comments on the article on the replacement of amphotericin B deoxycholate (AmBD) with lipid formulations of amphotericin (LFAB). Link of nephrotoxicity with morbidity; Avoidance of AmBD-associated toxicities; Adoption of LFAB for routine use.


Related Articles

  • Nephrotoxicity of Amphotericin B. Butler, William T.; Bennett, John E.; Alling, David W.; Wertlake, Paul T.; Utz, John P.; Hill II, George J. // Annals of Internal Medicine;Aug64, Vol. 61 Issue 2, p175 

    Studies the frequency and severity of renal abnormalities during and after treatment with amphotericin B. Impairment of renal function; Elevation in blood urea nitrogen and creatinine values; Relationship between the serum creatinine values and the total dose of amphotericin B; Frequency of...

  • Changes in Renal Morphology. Hill II, George J. // Annals of Internal Medicine;Aug64, Vol. 61 Issue 2, p349 

    Examines the renal toxicity of amphotericin B in humans and dogs. Dosage and duration of therapy; Interval between renal biopsy and treatment; Calcium deposition in intratubular debris; Dose-related axotemia in dogs receiving doses of amphotericin B; Renal histopathology and maximal blood urea...

  • Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections: Results of the Collaborative Exchange of Antifungal Research (CLEAR), an Industry-Supported Patient Registry. Pappas, Peter G. // Clinical Infectious Diseases;5/1/2005 Supplement, Vol. 40, pS379 

    This article focuses on the use of amphotericin B lipid complex (ABLC) for the treatment of invasive fungal infections. ABLC is a composition of amphotericin B and 2 phospholipids, dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol, in a 1:1 drug-to-lipid molar ratio. ABLC was...

  • Reply. Ostrosky-Zeichner, Luis; Marr, Kieren A.; Rex, John H.; Cohen, Stuart H. // Clinical Infectious Diseases;1/15/2004, Vol. 38 Issue 2, p306 

    Comments on the use of lipid formulations of amphotericin B in treating invasive fungal infections. Possibility of using continuous infusions of amphotericin B deoxycholate (AmBD); Limited comparative data supporting the efficacy of continuously infused AmBD; Link of short- and long-term...

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S.B.; Chapuis, F.; Decullier, E.; Revol, B.G.P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2005, Vol. 24 Issue 2, p119 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...

  • Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Wasan, Kishor; Wong, Joyce; Corr, Traci; Pritchard, Sheila // Cancer Chemotherapy & Pharmacology;Jan2006, Vol. 57 Issue 1, p120 

    Purpose: The objective of this study was to determine if total plasma and lipoprotein cholesterol (C) and triglyceride (TG) concentrations could predict the degree of nephrotoxicity caused by the antifungal agent amphotericin B (AmpB); and to use the average amount of potassium supplementation...

  • Clinical and Economic Outcomes of Conventional Amphotericin B-Associated Nephrotoxicity. Harbarth, Stephan; Burke, John P.; Lloyd, James F.; Evans, R. Scott; Pestotnik, Stanley L.; Samore, Matthew H. // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p120 

    A retrospective 9-year cohort study was conducted to identify the hospitalization costs, length of hospital stay, and mortality associated with nephrotoxicity (NT) among 494 inpatients who were treated with conventional amphotericin B (CAB). Survival regression methods were used to model the...

  • Comparison of Nephrotoxicity of Amphotericin B Products. Harrell, Colleen Carrigan; Honf-Kristufek, Lauryl // Clinical Infectious Diseases;3/15/2001, Vol. 32 Issue 6, p990 

    Focuses on a study which compared nephrotoxicity of amphotericin B lipid complex and conventional amphotericin B. Parameters for defining nephrotoxicity.

  • Reply to Messori et al. Mistro, Sostenes; Schooley, Robert T.; Badaro, Roberto // Clinical Infectious Diseases;Dec2013, Vol. 57 Issue 12, p1784 

    A letter to the editor is presented in response to the article "Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis," by A. Messori published in a previous issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics